Characterization of Participants treated with Ultomiris and Long term safety outcomes: an IPIG registry based study

First published: 31/03/2025

Last updated: 31/03/2025

Study Planned

Administrative details

EU PAS number

EUPAS1000000533

Study ID

1000000533

DARWIN EU® study

No

Study countries

- [ ] Argentina
- [ ] Australia
- [ ] Austria
- [ ] Belgium

- [ ] Canada
- [ ] China
- [ ] Colombia
- [ ] France
- [ ] Germany
- [ ] Greece
- [ ] Italy
- [ ] Japan
- [ ] Korea, Republic of
- [ ] Netherlands
- [ ] Saudi Arabia
- [ ] Spain
- [ ] Sweden
- [ ] Switzerland
- [ ] Taiwan
- [ ] Türkiye
- [ ] United Kingdom
- [ ] United States

Study description

This is a noninterventional cohort study utilizing data from the IPIG PNH Registry.

Adult and pediatric participants with PNH with a detected proportion of PNH cells (PNH clone) of at least 1% at registry enrollment, who have provided written informed consent, and who are not participating in an interventional clinical trial specific to PNH, are eligible for participation in the IPIG PNH Registry.

The primary study objectives are to characterize the safety of Ultomiris in participants in PNH and the incidence of targeted clinical outcomes among

participants with PNH. Secondary objectives include describing the demographic and clinical profile at treatment initiation for Ultomiris treated participants with PNH and assessing Ultomiris treatment patterns among participants with PNH.

Study status

Planned

Research institutions and networks

Institutions

Alexion Europe SAS

NA

Networks

NA

Contact details

Study institution contact

Alexion Europe SAS clinicaltrials@alexion.com

Study contact

clinicaltrials@alexion.com

Primary lead investigator

Alexion Europe SAS

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 22/01/2024

Study start date

Planned: 31/01/2025

Date of final study report

Planned: 20/06/2025

Sources of funding

- Pharmaceutical company and other private sector

Study protocol

ALX-PNH-501 PASS Protocol - Final - 14 June 2023.pdf(529.74 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Data collection methods:

Combined primary data collection and secondary use of data

Study design:

This non-interventional cohort study utilizes data from the multinational, multicenter, observational IPIG PNH registry

Main study objective:

Primary objectives include characterizing the safety of Ultomiris in participants with PNH.
Additionally, the study aims to characterize the incidence of targeted clinical putcomes (MAVE, TE, malignancy, serious infection, impaired renal function, impaired hepatic function, hemolysis, mortality, bone marrow transplant) among participants with PNH.

Study Design

Non-interventional study design
Cohort

Study drug and medical condition

Name of medicine
ULTOMIRIS

Study drug International non-proprietary name (INN) or common name
RAVULIZUMAB

Anatomical Therapeutic Chemical (ATC) code
(L04AJ02) ravulizumab
ravulizumab

Population studied

Short description of the study population

Adult and pediatric participants with PNH

Age groups

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adult and elderly population (≥18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

300

Study design details

Setting

Persons: Participants (adult and pediatric) with PNH diagnosis confirmed by flow cytometry and who meet the inclusion/exclusion criteria will be invited to participate in the IPIG PNH Registry.
All participants with PNH will be eligible, regardless of whether they are receiving PNH-specific therapy and regardless of what type of therapy they are receiving.

Place: Participants enrolled in the global IPIG PNH Registry

Inclusion Criteria:
Participants of any age and sex, with PNH with a detected proportion of PNH cells (PNH clone) of at least 1% at registry enrollment, initiating Ultomiris on or after enrollment into the Alexion or IPIG PNH Registries.

Ability to comprehend and sign consent or able to give assent to have data entered in the IPIG PNH Registry. Participants who are minors must have parent/legal guardian consent. Participants who are minors must be willing and able to give assent, if applicable as determined by the Ethics Committees/Institutional Review Boards (IECs/IRBs). Upon attaining adulthood, these participants must be re-consented.

Exclusion Criteria:
Participants currently enrolled in an interventional clinical study for treatment of PNH cannot be enrolled in the IPIG PNH Registry while enrolled/participating in the clinical study for PNH therapy.

Participants without known year of birth, sex, Ultomiris treatment status, or informed consent date.

Treatment groups: Participants will be categorized into treatment groups by prior Soliris treatment status: Prior Soliris treatment, without prior Soliris treatment, Unknown prior Soliris treatment.

Comparators

N/A

Outcomes

Participant demographics, medical history, clinical events, laboratory values, concomitant medication, prior treatment with Soliris, and Ultomiris dose will be summarized at initiation of Ultomiris using descriptive analyses. Treatment and registry discontinuation along with associated reasons, pregnancy and fetal outcomes, and SAEs collected during registry follow-up will also be summarized.

Clinical events, including death, MAVEs (including thrombosis), infection, malignancy, impaired renal function, impaired hepatic function, Ultomiris infusion reactions, hemolysis, pulmonary hypertension, and bone marrow transplant, will be summarized by event rates.

Data analysis plan

All analyses will be carried out using SAS® version 9.4 or higher. Statistical analysis will be descriptive only. No formal hypothesis testing will be performed.

Continuous variables will be characterized with number of non-missing observations, mean and standard deviation, median and interquartile range, minimum and maximum, and number of missing data. Categorical variables will be characterized by the frequency and percentage distribution in each category for non-missing data, as appropriate. The analysis will include 95% confidence intervals of means and percentages, as appropriate.

Event rates are calculated by: The total number of events and the total person-years during the follow-up period of interest will be determined. The event rate will be the number of events divided by the person-years.
Person-years are calculated under the definition of exposure for all participants included in the study population, regardless of whether they had an event.
The event rate will be calculated using a Poisson regression with over-dispersion or generalized estimating equations using a log link, as is

appropriate.

Data management

Data sources

Data source(s), other

IPIG PNH Registry (including retrospective data from the Alexion PNH registry)

Data sources (types)

Disease registry

Use of a Common Data Model (CDM)

CDM mapping

Yes

CDM Mappings

CDM name

CDISC SDTM

CDM website

https://www.cdisc.org/standards/foundational/sdtm

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No